# Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer

> **NCT01281943** · PHASE2 · WITHDRAWN · sponsor: **Washington University School of Medicine**

## Conditions studied

- Liver Neoplasms

## Interventions

- **DRUG:** Temsirolimus 25mg and Pegylated liposomal doxorubicin 25mg/m2

## Key facts

- **NCT ID:** NCT01281943
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-06
- **Primary completion:** 2012-07
- **Final completion:** 2014-05
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Doxil Shortage
- **Last updated:** 2013-07-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01281943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01281943, "Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01281943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*